UNSPSC 51281612: Elsamicin a or elsamitrucin

This classification denotes a topoisomerase-ii inhibitor and miscellaneous antineoplastic antibiotic with the molecular formula C33H35NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTV0FOB6NU, chemically known as 2-amino-2,6-dideoxy-3-o-methyl-d-galactose but generally known as elsamitrucin, which bears US NIH Compound Identifier 5362259. European Medicines Agency schedules Elsamitrucin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06493MIG.

UNSPSC 51281612 Elsamicin a or elsamitrucin, a Commodity code, shows little relevant recent activity in state and local procurement. The code's nominal scope does not align with the pharmaceutical and medical supply acquisitions posted under this classification. Recent opportunities tagged to the code include naloxone and drug deactivation systems (Seminole County, Florida IFB), generic pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance RFP), a direct-to-manufacturer prescription program RFI (Texas Health and Human Services Commission), and medical and first aid supplies for fire rescue operations (City of Tampa IFB). None of these solicitations reference elsamicin or elsamitrucin specifically, suggesting the code assignment reflects a data indexing mismatch rather than actual procurement demand for the commodity itself.

The opportunities that do appear under this code reveal that state and local health agencies, cooperative purchasing alliances, and emergency services departments are actively procuring pharmaceutical products, medical supplies, and drug management systems through competitive bidding and RFP processes. The City of Tampa's medical and first aid supplies procurement (Bid 26P00145, due March 13, 2026, estimated $700 million with a Small Local Business Enterprise set-aside) and MMCAP's generic pharmaceuticals RFP (due March 26, 2026, serving state and local facilities across multiple states including Oregon) demonstrate sustained demand in this product family, though targeted procurement for elsamicin specifically does not appear in current state and local records. Firms should verify code assignments when pursuing opportunities in pharmaceutical and medical supply procurement rather than rely on this nominal classification.